-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports by Yimaike ★ Invitation Letter2021 CSGCT Gene and Cell Therapy Medical Summit will be held in Shanghai ★ 4 cancer immunotherapies won by Gilead, USD 725 million to expand oncology pipelineYimai Meng broke the news on November 25, 2021 /Healthcare News/eMedClub News/--Recently, Affimed announced that its cord blood-derived natural killer cells (cbNK cells) are pre-combined with innate cell engager (ICE) AFM13.
Interim positive results were obtained in the phase I/II study of treated Hodgkin and non-Hodgkin lymphoma patients
.
The results of the trial showed that after the first treatment cycle, among the 12 patients who received the recommended dose of treatment, all patients achieved objective remission, including 7 patients with partial remission (PR), 5 patients with complete remission (CR), and complete remission rate.
Reached 42%
.
Natural killer (NK) cells are innate lymphocytes with cytotoxic effects and are involved in initiating adaptive immune responses
.
Once activated, NK cells secrete pro-inflammatory cytokines and trigger perforin/granzyme-induced lysis of target cells
.
They can precisely attack and eliminate abnormal cells, and at the same time can regulate the body's immune status and immune function, which shows that NK cells have the potential to act as "anti-cancer guardians"
.
Studies have shown that when other immune cells are disabled, NK cells can still cause severe damage to cancer, and the long-term survival rate of some of the deadliest cancers seems to be affected by the activity of NK cells and the genes that control them
.
In May of this year, the MD Anderson Cancer Center of the University of Texas in the United States published the latest research results in Clinical Cancer Research of the American Association for Cancer Research, showing that cytokine-activated donor cord blood-derived natural killer (cbNK) cells combine to target CD16a and The CD30 research bispecific antibody AFM13 has strong anti-tumor activity against CD30+ lymphoma cells
.
Recommended reading: Breaking through the limitation of curative effect, NK cells combined with double antibodies showed enhanced anti-tumor efficacyYi Maihei Technology AFM13 is a CD16/CD30 immune cell adapter molecule (engager), which is based on Affimed's ROCK® (Redirected Optimized Cell) Killing, the "first-in-class" tandem tetravalent bispecific antibody (Tandab) developed on the Redirected Optimization of Cell Killing) platform can bind CD16a on NK cells and CD30 on lymphoma cells
.
One advantage of this molecule is that it can be "tailored" to target different tumor targets, thereby giving NK cells the ability to treat different types of cancer
.
▲Video source: Affimed’s official website Affimed’s ROCK technology platform can quickly discover multispecific antibodies that bind to NK/T cells and tumor cell surface antigens at the same time.
Antibodies can interact with specific antigens on the surface of NK/T cells and tumor cell surfaces.
Antigen binding successfully recruits NK/T cells to the vicinity of tumor cells and promotes its killing effect
.
▲The tumor cell killing mechanism of the ROCK® platform (picture source: Affimed official website) As of October 31, 2021, there are 18 cases of CD30-positive relapsed or refractory Hodgkin's lymphoma (16 cases) and non-Hodgkin's lymphoma The patients (2 cases) received different doses of this innovative therapy
.
The results of the trial showed that 16 of 18 patients achieved objective remission (ORR), including 7 complete remission (CR) and 9 partial remission (PR)
.
Of the 12 patients treated with the recommended phase II dose level (108 cbNK cells/Kg combined with AFM13), 11 were Hodgkin’s lymphoma patients
.
The ORR of this cohort of patients when they completed the first cycle of treatment was 100%
.
In terms of safety, the treatment combination was well tolerated, and there were 5 cases of transient infusion-related reactions after a single injection of AFM13
.
However, there were no serious adverse reactions such as cytokine release syndrome, immune cell-related neurotoxicity syndrome, or graft-versus-host disease
.
"Patients included in this study have received a large number of pre-treatments with a median of 6 lines, and their disease progressed after treatment
.
" Dr.
Andreas Harstrick, Chief Medical Officer of Affimed, said: "It continues to be observed in these refractory patients.
We are encouraged by the remission of AACR.
These data are consistent with the data published on the AACR earlier this year
.
More importantly, we continue to observe the good safety of combination drugs, which is for patients who have received a large number of pre-treatments.
Very important, because they can no longer tolerate radical therapies
.
The combination of
ICE molecules and NK cells is part of our company's strategy to bring innovative therapies to patients in need
.
"It is worth mentioning that Affimed is based on ROCK technology.
The platform has developed a variety of new target candidate products for solid tumors and hematological tumors
.
▲Affimed company pipeline (picture source: Affimed official website) Reference materials: 1.
https:// 2-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13-for-cd30-positive-lymphomas/2.
https://clincancerres.
aacrjournals.
org/content/27/13/3744.
article-info
Interim positive results were obtained in the phase I/II study of treated Hodgkin and non-Hodgkin lymphoma patients
.
The results of the trial showed that after the first treatment cycle, among the 12 patients who received the recommended dose of treatment, all patients achieved objective remission, including 7 patients with partial remission (PR), 5 patients with complete remission (CR), and complete remission rate.
Reached 42%
.
Natural killer (NK) cells are innate lymphocytes with cytotoxic effects and are involved in initiating adaptive immune responses
.
Once activated, NK cells secrete pro-inflammatory cytokines and trigger perforin/granzyme-induced lysis of target cells
.
They can precisely attack and eliminate abnormal cells, and at the same time can regulate the body's immune status and immune function, which shows that NK cells have the potential to act as "anti-cancer guardians"
.
Studies have shown that when other immune cells are disabled, NK cells can still cause severe damage to cancer, and the long-term survival rate of some of the deadliest cancers seems to be affected by the activity of NK cells and the genes that control them
.
In May of this year, the MD Anderson Cancer Center of the University of Texas in the United States published the latest research results in Clinical Cancer Research of the American Association for Cancer Research, showing that cytokine-activated donor cord blood-derived natural killer (cbNK) cells combine to target CD16a and The CD30 research bispecific antibody AFM13 has strong anti-tumor activity against CD30+ lymphoma cells
.
Recommended reading: Breaking through the limitation of curative effect, NK cells combined with double antibodies showed enhanced anti-tumor efficacyYi Maihei Technology AFM13 is a CD16/CD30 immune cell adapter molecule (engager), which is based on Affimed's ROCK® (Redirected Optimized Cell) Killing, the "first-in-class" tandem tetravalent bispecific antibody (Tandab) developed on the Redirected Optimization of Cell Killing) platform can bind CD16a on NK cells and CD30 on lymphoma cells
.
One advantage of this molecule is that it can be "tailored" to target different tumor targets, thereby giving NK cells the ability to treat different types of cancer
.
▲Video source: Affimed’s official website Affimed’s ROCK technology platform can quickly discover multispecific antibodies that bind to NK/T cells and tumor cell surface antigens at the same time.
Antibodies can interact with specific antigens on the surface of NK/T cells and tumor cell surfaces.
Antigen binding successfully recruits NK/T cells to the vicinity of tumor cells and promotes its killing effect
.
▲The tumor cell killing mechanism of the ROCK® platform (picture source: Affimed official website) As of October 31, 2021, there are 18 cases of CD30-positive relapsed or refractory Hodgkin's lymphoma (16 cases) and non-Hodgkin's lymphoma The patients (2 cases) received different doses of this innovative therapy
.
The results of the trial showed that 16 of 18 patients achieved objective remission (ORR), including 7 complete remission (CR) and 9 partial remission (PR)
.
Of the 12 patients treated with the recommended phase II dose level (108 cbNK cells/Kg combined with AFM13), 11 were Hodgkin’s lymphoma patients
.
The ORR of this cohort of patients when they completed the first cycle of treatment was 100%
.
In terms of safety, the treatment combination was well tolerated, and there were 5 cases of transient infusion-related reactions after a single injection of AFM13
.
However, there were no serious adverse reactions such as cytokine release syndrome, immune cell-related neurotoxicity syndrome, or graft-versus-host disease
.
"Patients included in this study have received a large number of pre-treatments with a median of 6 lines, and their disease progressed after treatment
.
" Dr.
Andreas Harstrick, Chief Medical Officer of Affimed, said: "It continues to be observed in these refractory patients.
We are encouraged by the remission of AACR.
These data are consistent with the data published on the AACR earlier this year
.
More importantly, we continue to observe the good safety of combination drugs, which is for patients who have received a large number of pre-treatments.
Very important, because they can no longer tolerate radical therapies
.
The combination of
ICE molecules and NK cells is part of our company's strategy to bring innovative therapies to patients in need
.
"It is worth mentioning that Affimed is based on ROCK technology.
The platform has developed a variety of new target candidate products for solid tumors and hematological tumors
.
▲Affimed company pipeline (picture source: Affimed official website) Reference materials: 1.
https:// 2-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13-for-cd30-positive-lymphomas/2.
https://clincancerres.
aacrjournals.
org/content/27/13/3744.
article-info
